Form 8-K WILEY JOHN & SONS, INC. For: May 08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
May 8, 2017
(Date of Report)
(Date of earliest event reported)
JOHN WILEY & SONS, INC.
(Exact name of registrant as specified in its charter)
New York
(State or jurisdiction of incorporation)
0-11507
|
13-5593032
|
|
----------------------------------------------------
|
---------------------------------------------
|
|
Commission File Number
|
IRS Employer Identification Number
|
|
111 River Street, Hoboken NJ
|
07030
|
|
----------------------------------------------------
|
---------------------------------------------
|
|
Address of principal executive offices
|
Zip Code
|
|
Registrant’s telephone number, including area code:
|
(201) 748-6000
|
|
---------------------------------------------
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On May 8, 2017, Mark J. Allin, President and Chief Executive Officer of John Wiley & Sons, Inc. (the “Company”) and director on the Company’s Board of Directors, resigned from the Company.
(c) Effective May 8, 2017, the Board of Directors appointed Matthew S. Kissner, who has been serving as the Chairman of the Board, as the Company’s Interim Chief Executive Officer.
Mr. Kissner, 62, has been a Director on the Company’s Board since 2003 and Chairman since 2015. He is a former Executive Vice President and Group President of Pitney Bowes and has held leadership positions in the financial services industry.
A copy of the press release announcing the matters described above is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press release, dated May 8, 2017
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized
JOHN WILEY & SONS, INC.
|
|
Registrant
|
By
|
/s/ John A. Kritzmacher
|
|
John A. Kritzmacher
|
||
Chief Financial Officer and
|
||
Executive Vice President, Technology and Operations
|
Dated: May 8, 2017
|
Mark Allin resigns as President and CEO of Wiley
Matthew Kissner, Chairman of the Board, will serve as interim CEO
Hoboken, New Jersey—May 8, 2017—John Wiley and Sons, Inc. (NYSE: JWa and JWb), a global research and learning company, announced today that President and CEO Mark Allin has resigned for family reasons, effective immediately. Matthew Kissner, Chairman of the Board, has been named interim CEO. The Board has begun a search for Mr. Allin’s successor.
“The Board is thankful for Mark’s years of service and leadership,” said Mr. Kissner. “We understand and support his decision to step down for family reasons and are grateful for his many accomplishments. We wish him and his family the very best. I am confident that working with John Kritzmacher, our CFO and EVP, Technology and Operations and Wiley’s executive leadership team, the Company will enjoy continued success in the future.”
Mr. Allin said, “It has been an enormous privilege to have led Wiley during an important period of transformation and growth. I am proud to have worked with remarkable colleagues who are so committed to advancing learning and knowledge throughout the world.”
“With our engaged colleagues and industry leading knowledge and knowledge-enabled services, we are well positioned to meet the growing needs of our customers,” said Mr. Kissner. “We remain focused on driving profitable growth with a continued emphasis on quality and innovation to maximize shareholder value.”
“Mark Allin is leaving Wiley having made a significant contribution to our evolution,” said Jesse Wiley, Board member. “During his tenure, he has led significant changes to improve operations and drive future growth. He has been a tremendous asset to Wiley and we are grateful for his many contributions over 20 years. We wish him the very best.”
Mr. Allin is a 16-year Wiley veteran, joining the Company with the acquisition of Capstone Publishing (which he founded) in 2000. He went on to serve as Managing Director of Wiley Asia and Senior Vice-President Asia-Pacific, before being promoted to Executive Vice President, Professional Development in 2010 and then in 2015 Chief Operating Officer, followed by President and CEO.
Mr. Kissner has been a Wiley Director since 2003 and Chairman since 2015. His tenure includes service as chair of the Executive, Governance, Audit, and Compensation committees. He is a former Executive Vice President and Group President of Pitney Bowes and has held leadership positions in the financial services industry.
About Wiley
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at www.wiley.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paradies Lagardère and ARHT Expand Innovative Collaboration to Toronto Pearson International Airport
- 280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS
- Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!